Drug interactions
Anagrelide + Encorafenib
Severity: Major
Anagrelide and Encorafenib: major interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Encorafenib causes dose-dependent QTc prolongation, and anagrelide has a similar effect, so use together may raise the risk of torsades de pointes. The risk is greater with electrolyte abnormalities or underlying cardiac disease.
What this interaction means in plain words
Anagrelide and Encorafenib can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for.
Anagrelide belongs to Cardiovascular; Encorafenib belongs to Oncology.
Why it happens
Additive pharmacodynamic prolongation of the QT interval.
What to do
Avoid the combination if possible. If used together, monitor ECG and electrolytes and reduce or interrupt encorafenib per labeling if QTc becomes markedly prolonged.
What to ask your pharmacist
- Does the benefit of taking both outweigh the risk in my case?
- Do I need any blood test, ECG or other check while on both?
- What early warning signs should I watch for, and what should I do if they appear?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Anagrelide and Encorafenib, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 14 days on the web. No card needed.
Other interactions of Anagrelide
- Anagrelide + Panobinostat Contraindicated
- Anagrelide + Pimozide Contraindicated
- Anagrelide + Thioridazine Contraindicated
- Anagrelide + Vandetanib Contraindicated
- Abrocitinib + Anagrelide Major
- Alfuzosin + Anagrelide Major
Other interactions of Encorafenib
Frequently asked questions
Can I take Anagrelide with Encorafenib?
MediHelp rates the interaction as major. Anagrelide and Encorafenib can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for. Encorafenib causes dose-dependent QTc prolongation, and anagrelide has a similar effect, so use together may raise the risk of torsades de pointes. The risk is greater with electrolyte abnormalities or underlying cardiac disease.
How serious is the interaction between Anagrelide and Encorafenib?
MediHelp rates it major, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Avoid the combination if possible. If used together, monitor ECG and electrolytes and reduce or interrupt encorafenib per labeling if QTc becomes markedly prolonged.
What other medicines interact with Anagrelide?
MediHelp also lists interactions of Anagrelide with, for example, Panobinostat, Pimozide, Thioridazine. The full list is on the Anagrelide page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
